Clinical Trial Update
Tirzepatide and up to ~21% weight loss: the SURMOUNT-1 trial
In plain English
SURMOUNT-1 was the pivotal trial that established tirzepatide as an obesity treatment. Published in the New England Journal of Medicine in 2022, it enrolled 2,539 adults who had obesity, or were overweight with at least one weight-related complication, but who did not have diabetes. Participants were randomly assigned to weekly injections of tirzepatide at one of three doses — 5 mg, 10 mg or 15 mg — or to a matching placebo, with all groups also receiving lifestyle counselling. Treatment ran for 72 weeks.
Tirzepatide is a dual agonist: it activates both the GLP-1 receptor and the GIP receptor, two gut-hormone pathways involved in appetite and blood-sugar regulation. The trial set out to test whether engaging both pathways at once would produce weight loss beyond what single-pathway GLP-1 medicines had achieved.
The results were among the largest seen in a drug trial for obesity. Average body-weight reduction was 15.0% on the 5 mg dose, 19.5% on 10 mg and 20.9% on the highest 15 mg dose. Participants on placebo lost 3.1%. Put plainly, those on the top dose lost roughly a fifth of their starting body weight on average. The most common side effects were gastrointestinal — nausea, diarrhoea and constipation — and were mostly mild to moderate, typically appearing during the gradual dose-escalation phase.
Why it matters
SURMOUNT-1 mattered because the magnitude of weight loss approached territory previously associated only with bariatric surgery. A mean reduction of around 21% on the highest dose is substantially greater than the figures reported for earlier GLP-1-only agents, and it shifted clinical expectations of what pharmacotherapy could deliver.
The trial also helped reframe obesity as a condition responsive to targeted hormonal treatment rather than willpower alone. By acting on two gut-hormone receptors simultaneously, tirzepatide appeared to amplify the appetite-modulating effect seen with GLP-1 medicines. The data underpinned regulatory approval of tirzepatide for weight management (marketed as Zepbound) and informed how clinicians now weigh dose, tolerability and expected outcome when starting treatment. As with all the GLP-1-class agents, the findings describe results sustained while treatment continues — the trial does not speak to what happens after stopping.
Practical takeaways
- Tirzepatide is a dual GLP-1/GIP receptor agonist — it engages two gut-hormone pathways rather than one.
- Over 72 weeks, mean weight loss was 15.0% (5 mg), 19.5% (10 mg) and 20.9% (15 mg), against 3.1% on placebo.
- The trial enrolled adults with obesity or overweight-plus-complications, none of whom had diabetes.
- Side effects were chiefly gastrointestinal and mostly mild to moderate, clustering during dose escalation.
- The magnitude of weight loss on the highest dose approached levels previously seen only with bariatric surgery.
- Results reflect outcomes while treatment continued; the trial does not address weight after discontinuation.
Frequently Asked Questions
How much weight did people lose in SURMOUNT-1?
Over 72 weeks, average body-weight reduction was 15.0% on the 5 mg dose of tirzepatide, 19.5% on 10 mg and 20.9% on 15 mg. Participants taking placebo lost 3.1%. On the highest dose, the average participant lost roughly one-fifth of their starting body weight.
How is tirzepatide different from semaglutide?
Semaglutide acts on a single gut-hormone receptor, GLP-1. Tirzepatide is a dual agonist that activates both the GLP-1 and the GIP receptors. SURMOUNT-1 tested whether engaging both pathways together would deliver greater weight loss; the 15 mg dose produced a mean reduction of about 21%, higher than the figures reported for GLP-1-only agents in comparable trials.
Did participants in SURMOUNT-1 have diabetes?
No. SURMOUNT-1 specifically enrolled adults without type 2 diabetes who had obesity, or were overweight with at least one weight-related complication. A separate trial programme examined tirzepatide in people with diabetes.
Scientific References
2 sources- 1
Jastreboff AM, Aronne LJ, Ahmad NN, et al.
Tirzepatide Once Weekly for the Treatment of Obesity
New England Journal of Medicine · 387(3) · 2022PMID: 35658024
NEJM - 2
Wilding JPH, Batterham RL, Calanna S, et al.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
New England Journal of Medicine · 384(11) · 2021PMID: 33567185
NEJM
References open in a new tab. Content is reviewed against peer-reviewed literature as part of our editorial policy.
Not medical advice. This research summary is for general education. It describes findings from a published study and does not constitute clinical guidance. Treatment decisions require a licensed clinician who knows your full medical history.
Weekly Digest
Get Evidence-Based Metabolic Health Insights Weekly
Research-backed insights on metabolism, GLP-1 science, and sustainable weight management — once a week.
Related reading
Articles on this topic
How Tirzepatide Works: The Dual GLP-1/GIP Mechanism Explained
Tirzepatide activates two gut-hormone receptors at once — GLP-1 and GIP. Here is how that dual mechanism works, and why it may outperform GLP-1 alone.
Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?
SURMOUNT-1 and STEP 1 ran similar protocols. The headline numbers favor tirzepatide. The clinical picture is more nuanced.
Zepbound Clinical Trial Results: What SURMOUNT-1 Through 5 Tell Us
SURMOUNT-1 reported 20.9% mean body weight loss at 72 weeks. SURMOUNT-3 enrolled lifestyle-resistant patients. SURMOUNT-4 measured what happens after discontinuation. Here is the full picture from the program.
Using Mounjaro for Weight Loss Without Diabetes: What You Need to Know
Mounjaro and Zepbound contain the same molecule but carry different FDA indications. The distinction shapes prescribing, insurance coverage, and the clinical context of off-label use.